BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 11734300)

  • 1. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice.
    Fazzi R; Testi R; Trasciatti S; Galimberti S; Rosini S; Piras F; L'Abbate G; Conte A; Petrini M
    Leuk Res; 2002 Jan; 26(1):19-27. PubMed ID: 11734300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells.
    Fazzi R; Galimberti S; Testi R; Pacini S; Trasciatti S; Rosini S; Petrini M
    Leuk Res; 2002 Sep; 26(9):839-48. PubMed ID: 12127560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
    Janowska-Wieczorek A; Marquez LA; Nabholtz JM; Cabuhat ML; Montaño J; Chang H; Rozmus J; Russell JA; Edwards DR; Turner AR
    Blood; 1999 May; 93(10):3379-90. PubMed ID: 10233890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis.
    Fazzi R; Pacini S; Testi R; Azzarà A; Galimberti S; Testi C; Trombi L; Metelli MR; Petrini M
    Br J Haematol; 2003 Apr; 121(1):76-85. PubMed ID: 12670334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice.
    Brasel K; McKenna HJ; Charrier K; Morrissey PJ; Williams DE; Lyman SD
    Blood; 1997 Nov; 90(9):3781-8. PubMed ID: 9345066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of recombinant granulocyte colony-stimulating factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) on acute radiation hematopoietic injury in mice.
    Tanikawa S; Nakao I; Tsuneoka K; Nara N
    Exp Hematol; 1989 Sep; 17(8):883-8. PubMed ID: 2475360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor.
    Neben S; Marcus K; Mauch P
    Blood; 1993 Apr; 81(7):1960-7. PubMed ID: 7681707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
    Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
    Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.
    Van Epps DE; Bender J; Lee W; Schilling M; Smith A; Smith S; Unverzagt K; Law P; Burgess J
    Blood Cells; 1994; 20(2-3):411-23. PubMed ID: 7538347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor.
    Siena S; Bregni M; Brando B; Ravagnani F; Bonadonna G; Gianni AM
    Blood; 1989 Nov; 74(6):1905-14. PubMed ID: 2478216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytokine treatment (granulocyte colony-stimulating factor and stem cell factor) on hematopoiesis and the circulating pool of hematopoietic stem cells in mice.
    Drize N; Chertkov J; Samoilina N; Zander A
    Exp Hematol; 1996 Jun; 24(7):816-22. PubMed ID: 8647232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice.
    Carlo-Stella C; Di Nicola M; Magni M; Longoni P; Milanesi M; Stucchi C; Cleris L; Formelli F; Gianni MA
    Cancer Res; 2002 Nov; 62(21):6152-7. PubMed ID: 12414641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.